$AZN News

AstraZeneca Highlights Sustained Survival Benefit In Advanced Breast Cancer Study

AstraZenica To Present Updated Phase III SERENA-6 Trial Results At ASCO Annual Meeting June 2

AstraZeneca PLC (AZN) Presents at American Society of Clinical Oncology (ASCO) Annual Meeting 2026 - Slideshow

AstraZeneca Sees Encouraging Survival Trend In Liver Cancer Trial

FDA Approves Durvalumab In Combination With Bacillus Calmette-Guerin For High-Risk Non-Muscle Invasive Bladder Cancer

Daiichi Sankyo, AstraZeneca's Datroway Receives U.S. Approval To Treat Unresectable Or Metastatic Triple Negative Breast Cancer

Enhertu, Jointly Developed, Commercialized By Daiichi Sankyo And Astrazeneca, Recommended For Approval In EU By CHMP As Monotherapy For Treatment Of Adult Patients With HER2 Positive Solid Tumors

AstraZeneca To Present Phase III Data In Liver, Breast And Bladder Cancers And Potential Rare Disease Therapy At ASCO 2026

Why Pfizer Stock Still Looks Deeply Undervalued In 2026

AstraZeneca's BAXFENDY Approved In US As Aldosterone Synthase Inhibitor For Treatment Of Hypertension In Combination With Other Antihypertensive Medications

AstraZeneca's Baxfendy Wins FDA Approval As First-In-Class Aldosterone Synthase Inhibitor For Uncontrolled Hypertension

AstraZeneca's Imfinzi Combo Shows Survival Benefit In Pivotal Bladder Cancer Study

AstraZeneca Says Perioperative IMFINZI Plus IMJUDO And Neoadjuvant EV Shows Statistically And Clinically Meaningful Improvement In Event-Free Survival And Favorable Trend For Overall Survival

Owkin Expands AstraZeneca Collaboration Around K Pro AI Platform

AstraZeneca's Rare Disease Drug Shows Reduced Dependence On Calcium Supplements

Astrazeneca's Eneboparatide (AZP-3601) In CALYPSO Phase 3 Trial Met Its Composite Primary Endpoint, Demonstrating A Statistically Significant And Clinically Meaningful Normalization Of Albumin-adjusted Serum Calcium Levels And Independence From Supplements In Adults With Chronic Hypoparathyroidism

Mineralys: 'Hold' As Hypertension OSA Data Barely Delivers And AstraZeneca On The Move

AstraZeneca Prostate Drug Wins FDA Panel Backing As Breast Cancer Candidate Falters

Reported Earlier, AstraZeneca's TRUQAP Wins FDA Oncologic Drugs Advisory Committee Backing For PTEN-Deficient mHSPC; CAPItello-281 Shows 19% Risk Reduction In Disease Progression

Update On FDA Advisory Committee Vote On Camizestrant In Combination With A CDK4/6 Inhibitor For Advanced HR-Positive Breast Cancer; AstraZeneca Says FDA Did Not Reach Majority Vote On Benefit Risk Profile Of AstraZeneca's Camizestrant In Combination With CDK4/6 Inhibitor